These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1080 related articles for article (PubMed ID: 1314189)
1. Modulation of the expression of the VIP receptor by serum factors on the human melanoma cell line IGR39. Bellan C; Fabre C; Secchi J; Marvaldi J; Pichon J; Luis J Exp Cell Res; 1992 May; 200(1):34-40. PubMed ID: 1314189 [TBL] [Abstract][Full Text] [Related]
2. A human melanoma-derived cell line (IGR39) with a very high number of vasoactive-intestinal-peptide (VIP) receptors. 2. Effect of VIP on cAMP production and on cell-surface VIP-binding sites. Martin JM; Luis J; Marvaldi J; Pichon J; Pic P Eur J Biochem; 1989 Mar; 180(2):435-9. PubMed ID: 2538331 [TBL] [Abstract][Full Text] [Related]
3. A human melanoma-derived cell line (IGR39) with a very high number of vasoactive-intestinal-peptide (VIP) receptors. 1. Molecular characterization of the binding site. Luis J; Martin JM; el Battari A; Reynier M; Marvaldi J; Pichon J Eur J Biochem; 1989 Mar; 180(2):429-33. PubMed ID: 2538330 [TBL] [Abstract][Full Text] [Related]
4. Structural and functional analysis of the human vasoactive intestinal peptide receptor glycosylation. Alteration of receptor function by wheat germ agglutinin. Chochola J; Fabre C; Bellan C; Luis J; Bourgerie S; Abadie B; Champion S; Marvaldi J; el Battari A J Biol Chem; 1993 Feb; 268(4):2312-8. PubMed ID: 8381403 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of vasoactive intestinal peptide (VIP) binding on human melanoma cells IGR39 by nitric oxide: cGMP is not involved. Fouchier F; Pichon J; Forget P Eur J Cell Biol; 1994 Jun; 64(1):71-7. PubMed ID: 7957315 [TBL] [Abstract][Full Text] [Related]
6. Modifications of the binding properties of the human VIP receptor of IGR39 cells by sulfhydryl reagents. Fouchier F; Forget P; Pic P; Marvaldi J; Pichon J Eur J Cell Biol; 1992 Dec; 59(2):382-8. PubMed ID: 1337321 [TBL] [Abstract][Full Text] [Related]
7. Effects of vasoactive intestinal peptide on adenosine 3',5'-monophosphate, ornithine decarboxylase, and cell growth in a human colon cell line. Yu D; Seitz PK; Selvanayagam P; Rajaraman S; Townsend CM; Cooper CW Endocrinology; 1992 Sep; 131(3):1188-94. PubMed ID: 1324153 [TBL] [Abstract][Full Text] [Related]
8. Restricted localization of functional vasoactive intestinal peptide (VIP) receptors in in vitro differentiated human colonic adenocarcinoma cells (HT29-D4). Fantini J; Martin JM; Luis J; Rémy L; Tirard A; Marvaldi J; Pichon J Eur J Cell Biol; 1988 Aug; 46(3):458-65. PubMed ID: 2846304 [TBL] [Abstract][Full Text] [Related]
9. Glucocorticoids upregulate the high affinity receptors for vasoactive intestinal peptide (VIP) on human mononuclear leucocytes in vitro. Wiik P Regul Pept; 1991 Jul; 35(1):19-30. PubMed ID: 1656488 [TBL] [Abstract][Full Text] [Related]
10. Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer cells. Gespach C; Bawab W; de Cremoux P; Calvo F Cancer Res; 1988 Sep; 48(18):5079-83. PubMed ID: 2842044 [TBL] [Abstract][Full Text] [Related]
11. Cycloheximide induces accumulation of vasoactive intestinal peptide (VIP) binding sites at the cell surface of a human colonic adenocarcinoma cell line (HT29-D4). Evidence for the presence of an intracellular pool of VIP receptors. Luis J; Martin JM; el Battari A; Fantini J; Giannellini F; Marvaldi J; Pichon J Eur J Biochem; 1987 Sep; 167(2):391-6. PubMed ID: 3040409 [TBL] [Abstract][Full Text] [Related]
12. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis. Zawilska JB; Niewiadomski P; Nowak JZ Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130 [TBL] [Abstract][Full Text] [Related]
13. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells. Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448 [TBL] [Abstract][Full Text] [Related]
14. VIP receptor subtypes in mouse cerebral cortex: evidence for a differential localization in astrocytes, microvessels and synaptosomal membranes. Martin JL; Feinstein DL; Yu N; Sorg O; Rossier C; Magistretti PJ Brain Res; 1992 Jul; 587(1):1-12. PubMed ID: 1326373 [TBL] [Abstract][Full Text] [Related]
15. Characterization of binding sites for VIP-related peptides and activation of adenylate cyclase in developing pancreas. Le Meuth V; Farjaudon N; Bawab W; Chastre E; Rosselin G; Guilloteau P; Gespach C Am J Physiol; 1991 Feb; 260(2 Pt 1):G265-74. PubMed ID: 1847591 [TBL] [Abstract][Full Text] [Related]
16. Functional vasoactive intestinal polypeptide (VIP) receptors in human neuroblastoma subclones that contain VIP precursor mRNA and release VIP-like substances. Muller JM; Lolait SJ; Yu VC; Sadée W; Waschek JA J Biol Chem; 1989 Mar; 264(7):3647-50. PubMed ID: 2537287 [TBL] [Abstract][Full Text] [Related]
17. Ontogenic development of vasoactive intestinal peptide receptors in rat intestinal cells and liver. Chastre E; Emami S; Rosselin G; Gespach C Endocrinology; 1987 Dec; 121(6):2211-21. PubMed ID: 2824182 [TBL] [Abstract][Full Text] [Related]
18. Vasoactive intestinal peptide and intraocular pressure: adenylate cyclase activation and binding sites for vasoactive intestinal peptide in membranes of ocular ciliary processes. Mittag TW; Tormay A; Podos SM J Pharmacol Exp Ther; 1987 Apr; 241(1):230-5. PubMed ID: 3033201 [TBL] [Abstract][Full Text] [Related]
19. Functional receptors for vasoactive intestinal peptide on human osteosarcoma cells. Hohmann EL; Tashjian AH Endocrinology; 1984 Apr; 114(4):1321-7. PubMed ID: 6323142 [TBL] [Abstract][Full Text] [Related]
20. Carbachol-induced down-regulation of high-affinity receptors for vasoactive intestinal peptide. Murakami M; Vinayek R; Jensen RT; Gardner JD Am J Physiol; 1989 Sep; 257(3 Pt 1):G402-8. PubMed ID: 2551183 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]